Possible reasons for the lack of a robust antitumor response to PD-1 blockade in pMMR mCRC include the relative absence of infiltrating CD8+ T cells in tumors [10, 11] and the lower tumor mutation burden [12, 13]. Here, CD8A is linked to neoplasm.